In this regard, ADCs as tissue‐specific chemotherapeutics represent a sophisticated strategy to maximise immunogenic cell death [28] and improve the recruitment and activity of CD8+ effector T cells in the tumour core [29]. This evidence concerns the gene CD8A and neoplasm.